Charles Cherington - 10 Feb 2026 Form 4 Insider Report for Ernexa Therapeutics Inc. (ERNA)

Role
10%+ Owner
Signature
/s/ Charles Cherington
Issuer symbol
ERNA
Transactions as of
10 Feb 2026
Net transactions value
+$2,000,000
Form type
4
Filing time
17 Feb 2026, 21:14:34 UTC
Previous filing
11 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cherington Charles 10%+ Owner 200 BERKLEY STREET, 26TH FLOOR, BOSTON /s/ Charles Cherington 17 Feb 2026 0001448698

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERNA Common Stock Purchase $2,000,000 +4,000,000 +144% $0.5000 6,779,440 10 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Warrants to Purchase Common Stock Purchase +4,000,000 4,000,000 10 Feb 2026 Common Stock 4,000,000 $0.6800 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026.
F2 The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50.
F3 The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.

Remarks:

This form is being filed late due to delays encountered during the Reporting Person's initial enrollment and account authorization within the SEC's EDGAR Next System.